Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Banales, J.M.; Marin, J.J.G.; Lamarca, A.; Rodrigues, P.M.; Khan, S.A.; Roberts, L.R.; Cardinale, V.; Carpino, G.; Andersen, J.B.; Braconi, C.; et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 557–588. [Google Scholar] [CrossRef] [PubMed]
- Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010, 362, 1273–1281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.C.; Chen, M.H.; Yeh, C.N.; Hsiao, M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020, 10, 1377. [Google Scholar] [CrossRef] [PubMed]
- Chiang, N.J.; Chen, L.T.; Shan, Y.S.; Yeh, C.N.; Chen, M.H. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021, 11, 97. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.E.; Pan, Y.R.; Yeh, C.N.; Lunec, J. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules 2020, 10, 1474. [Google Scholar] [CrossRef] [PubMed]
- Huang, W.K.; Yeh, C.N. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. Biomolecules 2020, 10, 1396. [Google Scholar] [CrossRef] [PubMed]
- Pan, Y.R.; Wu, C.E.; Yeh, C.N. ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase theta Deficiency-Dependent Manner. Biomolecules 2020, 10, 1529. [Google Scholar] [CrossRef] [PubMed]
- Lane, D.P. Cancer. p53, guardian of the genome. Nature 1992, 358, 15–16. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wu, C.-E.; Yeh, C.-N. Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules 2021, 11, 1626. https://doi.org/10.3390/biom11111626
Wu C-E, Yeh C-N. Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules. 2021; 11(11):1626. https://doi.org/10.3390/biom11111626
Chicago/Turabian StyleWu, Chiao-En, and Chun-Nan Yeh. 2021. "Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial" Biomolecules 11, no. 11: 1626. https://doi.org/10.3390/biom11111626